[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infertility\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infertility":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,140,0,25,[9,53,77,101,130,157,180,219,244,268,293,322,356,380,400,420,445,469,497,521,540,565,594,632,666],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100644889","endometrial-peristalsis-and-pregnancy-outcomes-in-hormone-replacement-therapy-hrt---frozen-embryo-transfer-fet-cycles-100644889",false,"NCT07675213","Endometrial Peristalsis and Pregnancy Outcomes in Hormone Replacement Therapy (HRT) - Frozen Embryo Transfer (FET) Cycles","Correlation Between Endometrial Peristalsis And Pregnancy Outcomes In Patients Undergoing Frozen Embryo Transfer With Hormone Replacement Therapy for Endometrial Preparation Protocol","CONCO","Inclusion Criteria:\n\n* Women aged 18 - 42 years old\n* Scheduled for frozen embryo transfer cycles using hormone replacement therapy protocol\n* Transferred no more than two cleavage embryos or one good-quality blastocyst or no more than two poor-quality blastocysts\n* Provision of written informed consent to participate\n\nExclusion Criteria:\n\n* Having an allergy and contraindications for exogenous hormone administration (e.g., breast cancer, thromboembolic disease)\n* Cycles with preimplantation genetic testing, oocyte donation, or in vitro maturation\n* Having untreated uterine or adnexal abnormalities (e.g., intrauterine adhesions, unicornuate\u002F bicornuate\u002F arcuate uterus, endometrial polyp, large leiomyoma ≥5 cm in diameter, hydrosalpinx, endometrial hyperplasia)\n* Use of uterine relaxants or intralipid infusion during the embryo transfer process\n* Use of a GnRH-agonist for downregulation within one month","FEMALE","18 Years","42 Years",{"count":22,"type":23},442,"ESTIMATED","OBSERVATIONAL","Endometrial peristalsis may influence embryo implantation and pregnancy outcomes, but its role during hormone replacement therapy (HRT)-prepared frozen embryo transfer (FET) cycles remains unclear. This prospective observational study will assess endometrial peristalsis at predefined time points during HRT-prepared FET cycles using transvaginal ultrasonography and evaluate its association with pregnancy outcomes. The study aims to clarify the clinical significance of endometrial peristalsis in HRT-prepared FET cycles and to provide evidence supporting endometrial assessment in assisted reproductive technology.",[27,28,29,30,31,32,33],"Infertility","Endometrial Peristalsis","Uterine Contraction","Endometrial Waves","Frozen Embryo Transfer (FET)","Uterine Peristalsis","Hormone Replacement Therapy (HRT)",[35,36,37,38,39],"endometrial peristalsis","uterine contractions","endometrial waves","frozen embryo transfer","artificial cycles","NOT_YET_RECRUITING","2026-06-29",{"date":43,"type":44},"2026-07-01","ACTUAL",{"date":46,"type":23},"2026-06-30",{"date":48,"type":23},"2027-12-01",{"name":50,"class":51},"Mỹ Đức Hospital","OTHER",1,{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100635739","ultra-rapid-blastocyst-vitrification-pilot-randomized-study-100635739","NCT07556601","Ultra-rapid Blastocyst Vitrification: Pilot Randomized Study","Clinical Validation of Ultra-rapid Blastocyst Vitrification: a Randomized Pilot Study in Oocyte Donation Cycles","Inclusion Criteria:\n\n* Recipients of donor oocytes\n* Blastocysts suitable for cryopreservation\n\nExclusion Criteria:\n\n* Cycles involving PGT\n* Cycles not reaching blastocyst stage.","50 Years",{"count":62,"type":23},80,"INTERVENTIONAL",[65],"NA","Blastocyst vitrification is standard in assisted reproduction, but clinical data on ultra-rapid vitrification are limited. This pilot study evaluates the safety, feasibility, and preliminary clinical performance of an ultra-rapid blastocyst vitrification protocol compared with the standard approach.",[27],"RECRUITING",{"date":46,"type":44},{"date":71,"type":44},"2026-06-01",{"date":73,"type":23},"2028-03",{"name":75,"class":51},"Fundacion Dexeus",2,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":63,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":76},"100629736","safety-evaluation-of-the-hypersperm-sperm-preparation-procedure-for-in-vitro-fertilization-100629736","NCT07478549","Safety Evaluation of the HyperSperm Sperm Preparation Procedure for In Vitro Fertilization","Prospective, Multicenter, Randomized Clinical Trial Evaluating the Safety of the HyperSperm Sperm Preparation Procedure.","Inclusion Criteria:\n\nGeneral\n\n* Couples undergoing in vitro fertilization (IVF) treatment.\n* Planned use of fresh sperm samples obtained by masturbation.\n\nFemale\n\n* Age between 20 and 42 years.\n* Antral follicle count ≥ 4.\n* Eligible for ovarian stimulation and embryo transfer.\n\nMale\n\n* Age between 20 and 45 years.\n* Fresh semen sample (not cryopreserved).\n* Pre-processing sperm concentration ≥ 5 × 10⁶ sperm\u002FmL.\n\nExclusion Criteria:\n\nGeneral\n\n* Active sexually transmitted infection (STI).\n* Use of donor sperm.\n* Medical conditions contraindicating pregnancy or the IVF procedure.\n\nFemale\n\n* Uterine anomalies associated with distortion of the uterine cavity.\n* Absence of one ovary or functional disorders preventing ovulation.\n* Diabetes mellitus or other metabolic disorders.\n* Recurrent pregnancy loss, defined as more than two clinical pregnancies without live birth.\n\nMale\n\n\\- Any medical condition affecting semen quality that, in the investigator's opinion, may interfere with study participation.","ALL","20 Years","45 Years",{"count":88,"type":23},202,[65],"Prospective, multicenter, randomized clinical study evaluating the safety of a novel sperm preparation method for in vitro fertilization (IVF), compared to standard sperm preparation procedures.",[27],"2026-06-23",{"date":94,"type":44},"2026-06-26",{"date":96,"type":23},"2026-12",{"date":98,"type":23},"2028-05",{"name":100,"class":51},"Fecundis Lab SL",{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":18,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":52},"100473109","biorepository-in-participants-who-undergo-otc-for-gonadotoxic-therapy-100473109","NCT05440617","Biorepository in Participants Who Undergo OTC for Gonadotoxic Therapy","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Provision of signed and dated informed consent\u002Fassent form.\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n* Subjects who have planned to undergo OTC for gonadotoxic therapy based on current standard of care.\n\nEXCLUSION CRITERIA:\n\n-An individual who meets any of the following criteria will be excluded from participation in this study:\n\n--Adults subjects with psychological, psychiatric, or other conditions which prevent giving fully informed consent.","4 Years","35 Years",{"count":110,"type":23},100,"Background:\n\nMedical advances have improved survival rates for many cancers and other illnesses. This means that more people are coping with the long-term effects of these treatments. Some treatments can cause female infertility. Ovarian tissue cryopreservation (OTC) may help. Before undergoing a treatment that may damage their fertility, patients may opt to freeze a sample of ovarian tissue. The tissue contains immature egg cells. When thawed, the tissue can be reimplanted. This procedure can help women become pregnant.\n\nObjective:\n\nThis natural history study will create a databank of ovarian tissue. The NIH will provide OTC as a clinical service. The NIH will also request a portion of the tissue to use for research.\n\nEligibility:\n\nFemales aged 4 to 35 who opt to have OTC before receiving cancer treatment.\n\nDesign:\n\nParticipants will be screened. Their existing medical records will be reviewed.\n\nThey will be asked if they want to donate a portion of their ovarian tissue for research. No more than 20% of the tissue collected will be taken for research. Some other tissues that would otherwise be discarded will also be kept.\n\nMedical data from each participant may also be collected and stored in the database. This data may include results of routine blood tests, imaging tests, and other information. The data will be coded for privacy.\n\nParticipants will answer a questionnaire. They will be asked about their fertility treatment and general health. The survey takes about 30 minutes.\n\nThey will repeat the questionnaire once a year for 30 years.",[113,27,114],"Acute Ovarian Failure","Early Menopause And Infertility In Females After Treatment For Childhood Cancer",[116,117,118,119,120],"Ovarian Tissue Preservation","Cancer Survivors And Infertility","Acute Ovarian Failure In The Childhood Cancer Survivor Study","Ovarian Failure After Radiation","Natural History",{"date":122,"type":44},"2026-06-24",{"date":124,"type":44},"2022-07-22",{"date":126,"type":23},"2041-09-21",{"name":128,"class":129},"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","NIH",{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":12,"sex":84,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":141,"conditions":142,"keywords":146,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":4,"leadSponsor":155,"locationsCount":76},"100171064","inherited-reproductive-disorders-100171064","NCT01500447","Inherited Reproductive Disorders","The Molecular Basis of Inherited Reproductive Disorders","* INCLUSION CRITERIA:\n\nThe essential inclusion criteria include:\n\n1. failure to go through a normal, age-appropriate, spontaneous puberty and low sex steroid levels in the setting of low\u002Fnormal gonadotropins (due to substantial variability among patient presentations, this will be based on the clinical judgement of the Investigator), or\n2. abnormally early development of puberty, or\n3. normal puberty with subsequent development of low gonadotropin levels, or\n4. individuals with features indicating an increased risk of hypogonadotropic hypogonadism.\n5. Family members: both affected and unaffected family members are strongly encouraged to participate.\n\nEXCLUSION CRITERIA:\n\nSince hypogonadotropic hypogonadism is a rare condition, this protocol remains open to enrollment so that we may study all subjects that are both qualified and interested in participating.\n\nBecause HH represents a spectrum, where associated clinical findings may provide phenotypic clues to the assessment of inheritability and underlying physiology, exclusion criteria are very limited:\n\n* Patients who have additional pituitary deficiencies, effectively ruling out isolated GnRH deficiency, whether these deficiencies are congenital or acquired (e.g. secondary to malignancy, infection, or irradiation).\n* Patients who are taking medications known to affect GnRH secretion, such as corticosteroids or continuous opiate administration (or were taking them at the time of diagnosis).","6 Weeks","120 Years",{"count":140,"type":23},850,"Background:\n\n\\- During puberty, children begin to develop into adults. Problems with the hormones released during puberty can affect the reproductive system. Some people have low hormone levels that severely delay or prevent puberty. Others start puberty abnormally early. Other people may have a normal puberty but develop reproductive disorders later in life. Researchers want to study people with reproductive disorders to learn more about how these disorders may be inherited.\n\nObjectives:\n\n\\- To learn how reproductive system disorders may be inherited.\n\nEligibility:\n\n* People with one of the following problems:\n* Abnormally early puberty\n* Abnormally late or no puberty\n* Normal puberty with hormonal problems that develop later in life\n* People who have not yet had puberty but have symptoms that indicate low hormone levels.\n\nDesign:\n\n* Participants will provide a blood sample for testing. They will complete a questionnaire about their symptoms. They will also have a scratch-and-sniff test to study any problems with their ability to smell.\n* Participant medical records will be reviewed. Participants will also provide a family medical history.\n* Family members of those in the study may be invited to participate.\n* Treatment will not be provided as part of this study.",[143,27,144,145],"Genetic Disorder","Hypogonadism","Amenorrhea",[147,148,149,150,151,120],"Hypogonadotropic Hypogonadism","Kallmann Syndrome","Delayed Puberty","Hypothalamic Amenorrhea","Precocious Puberty",{"date":122,"type":44},{"date":154,"type":44},"2012-04-25",{"name":156,"class":129},"National Institute of Environmental Health Sciences (NIEHS)",{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":165,"conditions":166,"keywords":168,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":4},"100644155","outcomes-of-embryos-created-from-abnormally-fertilized-oocytes-100644155","NCT07666243","Outcomes of Embryos Created From Abnormally Fertilized Oocytes","Inclusion Criteria:\n\n* Underwent in vitro fertilization which resulted in a blastocyst derived from an abnormally fertilized embryo",{"count":164,"type":23},92,"The purpose of this study is to retrospectively analyze data from multiple clinics in a fertility network on embryos that were created from abnormally fertilized oocytes (AFO) including the rate of transfers and any clinical outcomes in order to inform providers in their decision making regarding AFOs.",[167,27],"Abnormal Fertilization",[169,170],"Fertility","Reproductive Medicine","2026-06-22",{"date":122,"type":44},{"date":174,"type":23},"2026-06",{"date":176,"type":23},"2027-06",{"name":178,"class":179},"Inception Fertility Research Institute, LLC","INDUSTRY",{"id":181,"slug":182,"hasResults":12,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":188,"sex":18,"minAge":19,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":63,"phases":192,"briefSummary":193,"conditions":194,"keywords":200,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":52},"100528791","hyaluronan-enriched-medium-and-euploid-blastocyst-transfers-100528791","NCT06165367","Hyaluronan-enriched Medium and Euploid Blastocyst Transfers","Impact of Hyaluronan-enriched Medium on Pregnancy Outcomes Following Euploid Blastocyst Transfers","GluePloid","Inclusion Criteria:\n\n* All frozen embryo transfer (FET) cycles with euploid blastocysts biopsied and vitrified on Day 5 after PGT-A.\n* Rank of randomization based on embryo quality.\n* Only hormonal replacement theraphy (HRT) cycle regimen.\n* Women aged 18 years to 46 years.\n* Having at least 1 chromosomally normal vitrified blastocyst(s) on Day 5 available for transfer.\n* All sperm samples.\n* BMI between 18 and 35.\n\nExclusion Criteria:\n\n* FET cycles with preimplantation genetic testing for monogenic disorders (PGT-M) and for structural rearrangements (PGT-SR).\n* FET cycles with mosaic \u002F aneuploid blastocysts.\n* FET cycles with unknown outcome.\n* FET cycles with Day 6 or Day 7 biopsied blastocysts.\n* FET with patients' endometrium preparation with treatments other than HRT.\n* FET where PGT-A was performed for gender selection.",true,"46 Years",{"count":191,"type":23},783,[65],"It has been proposed that enriching transfer media with hyaluronan (EmbryoGlue medium) improves pregnancy outcomes compared with media containing lower concentrations of this molecule. However, none of previous studies included preimplantation genetic testing for aneuploidy (PGT-A) embryos. In order to investigate the impact of this hyaluronan-enriched on pregnancy outcomes, it is essential to evaluate its efficacy on euploid-only embryo transfers. The aim of the present study is to evaluate whether a short period of exposure of euploid blastocysts to EmbryoGlue prior to and during transfer positively impact on pregnancy outcomes of frozen embryo transfer (FET) cycles.",[27,195,196,197,198,199],"Implantation Rate","Clinical Pregnancy Rate","Live Birth Rate","Blastocysts","FET",[201,202,203,204,205,206,207,208,209,210],"HRT","PGT-A","Next-generation sequencing (NGS)","Miscarriage rate","single embryo transfer (SET)","EmbryoGlue","BMI","Embryo quality","Hyaluronan-enriched medium","Transfer medium",{"date":212,"type":44},"2026-06-25",{"date":214,"type":44},"2024-01-15",{"date":216,"type":23},"2026-12-31",{"name":218,"class":51},"ART Fertility Clinics LLC",{"id":220,"slug":221,"hasResults":12,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":12,"sex":226,"minAge":19,"maxAge":86,"enrollmentInfo":227,"targetDuration":4,"studyType":63,"phases":229,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":52},"100644208","effects-of-visceral-osteopathic-massage-on-semen-parameters-and-hemodynamics-factors-in-varicocele-100644208","NCT07665905","Effects of Visceral Osteopathic Massage on Semen Parameters and Hemodynamics Factors in Varicocele","Investigation of the Effects of Visceral Osteopathic Massage Techniques on Semen Parameters and Hemodynamic Factors in Men With Varicocele: A Randomized Controlled Study","Inclusion Criteria:\n\n1. Male individuals aged 18-45 years.\n2. Diagnosis of varicocele confirmed by clinical examination and Doppler Ultrasound.\n3. Not being considered a candidate for surgery by a urology specialist.\n4. Following a follow-up protocol based on spermiogram results.\n5. Having at least one varicocele-related abnormality in spermiogram parameters according to WHO 2021 standards.\n6. Providing voluntary consent to participate in the study.\n\nExclusion Criteria:\n\n1. History of prior inguinal or scrotal surgery.\n2. Presence of active urogenital infection or malignancy.\n3. History of spinal or abdominal surgery that would contraindicate complementary medicine interventions.\n4. Having systemic inflammatory, rheumatologic, or endocrinologic diseases.\n5. Receiving additional medical or surgical intervention during the study period beyond routine medical treatment.\n6. Sperm quality changes due to hypogonadotropic causes.\n7. Use of prescribed purified flavonoid fraction venotonics for venous congestion and endothelial dysfunction.\n8. Use of antioxidant supplements (e.g., L-carnitine, L-acetylcarnitine, Ubiquinol, etc.) intended to improve sperm quality.\n9. Refusal to participate in the study.","MALE",{"count":228,"type":23},32,[65],"The project aims to evaluate the effects of a visceral osteopathic manual therapy (VOM) protocol on semen parameters and testicular hemodynamic indicators in men diagnosed with varicocele. Varicocele, the most common correctable cause of male infertility, is a progressive vascular pathology characterized by dilation of the pampiniform plexus veins and venous reflux. Multifactorial mechanisms such as venous valve insufficiency, increased intra-abdominal pressure, microcirculatory impairment, and oxidative stress play a role in the pathophysiology of varicocele. Therefore, the present study investigates the clinical effectiveness of a non-invasive rehabilitation approach aimed at regulating intra-abdominal pressure and improving pelvic venous drainage. The study will be conducted using a prospective, randomized controlled clinical design, including male participants aged 18-45 years diagnosed with varicocele. The intervention group will receive visceral osteopathic manual therapy techniques two times per week for eight weeks, while the control group will receive lifestyle recommendations only. Before and after the intervention, semen analysis results, sperm morphology, motility parameters, and testicular venous hemodynamic measurements obtained by color Doppler ultrasonography will be compared. Parametric and non-parametric statistical methods will be used in the analyses.\n\nThis project aims to generate clinical evidence regarding conservative, complementary medicine-based treatment options in the field of male infertility. Compared to studies on female reproductive health, research focusing on male reproductive health is more limited; therefore, this study is expected to contribute to the literature in this area. The results are anticipated to support the development of a cost-effective and accessible model for infertility treatment processes. In addition, the project aims to provide scientific data for the development of sustainable reproductive health approaches in terms of health economics in Türkiye. The study seeks to determine the effects of visceral osteopathic manual therapy on varicocele-related semen parameters and hemodynamic variables and to contribute to the development of new evidence-based approaches in the management of male infertility.",[232,27],"Varicocele",[234,232,27,235],"Osteopathic Physicians","Men's Health","2026-06-18",{"date":122,"type":44},{"date":239,"type":23},"2026-09-01",{"date":241,"type":23},"2027-11-01",{"name":243,"class":51},"Ankara Yildirim Beyazıt University",{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":12,"sex":226,"minAge":19,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":63,"phases":253,"briefSummary":254,"conditions":255,"keywords":257,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":266,"locationsCount":52},"100598632","intelliwell-an-ai-assisted-imaging-platform-for-detection-and-location-of-ultra-rare-testicular-sperm-in-surgical-specimens-100598632","NCT07074015","IntelliWell: An AI-Assisted Imaging Platform for Detection and Location of Ultra-Rare Testicular Sperm in Surgical Specimens","IntelliWell: An AI-Assisted Microwell Platform for Label-Free Localization of Ultra-Rare Sperm in Non-Obstructive Azoospermia Micro-TESE Specimens","Inclusion Criteria:\n\n1. Male subjects presenting to Brigham and Women's or Faulkner urology clinic with infertility with clinical non-obstructive azoospermia (clinical diagnosis based on two semen analyses, physical examination, and hormonal testing).\n2. Male subjects undergoing micro-surgical testicular sperm extraction surgery at Brigham and Women's Hospital.\n3. Surgically extracted sperm which are not found to have clinically usable quantities of sperm after standard of care manual processing for which samples would otherwise be discarded and the procedure deemed unsuccessful.\n\nExclusion Criteria:\n\n1\\. Female subject (with whom male subjects intends to conceive with surgically extracted sperm) cannot or will not provide her informed consent for study participation. She will undergo ICSI at BWH with BWH embryology.",{"count":252,"type":23},20,[65],"This study will help determine whether an AI-assisted microwell platform (IntelliWell) can identify rare sperm cells in testicular samples found to not have sperm by conventional analysis. Instead of discarding testicular tissue which was found to be non-sperm bearing by conventional analysis the testicular tissue will be processed using IntelliWell and, if sperm is found and verified by embryologists, it may be used for intracytoplasmic sperm injection (ICSI).",[27,256],"Azoospermia",[258,259,260],"infertility","azoospermia","micro-TESE","2026-06-17",{"date":171,"type":44},{"date":264,"type":44},"2026-04-16",{"date":48,"type":23},{"name":267,"class":51},"Brigham and Women's Hospital",{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":275,"targetDuration":4,"studyType":63,"phases":277,"briefSummary":279,"conditions":280,"keywords":281,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":292},"100619146","phase-3-a-study-to-compare-the-efficacy-and-safety-of-follitropin-alfalutropin-alfa-versus-hmg-in-japanese-participants-with-lh-and-fsh-deficiency-undergoing-art-hinata-100619146","NCT07340827","A Study to Compare the Efficacy and Safety of Follitropin Alfa\u002FLutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)","A Parallel-group Treatment, 2-arm Study to Compare the Efficacy and Safety of Follitropin Alfa and Lutropin Alfa Fixed Dose Combination Versus hMG for Inducing Follicular Development in Japanese Participants With LH and FSH Deficiency Undergoing ART","Inclusion Criteria:\n\n* Participants who are premenopausal wishing to conceive\n* Participants with maximum 1 previous stimulation for assisted reproductive technology (ART) without pregnancy\n* Japanese Participants\n* Participants are women with Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) deficiency congenital or acquired\n* Participants have a vaginal ultrasound scan showing both ovaries and no clinically significant uterine abnormality and a normal antral follicle count (AFC) of at least 5 follicles 2 to 10 millimeter (mm) in diameter per ovary\n* A semen analysis of the male partner been performed within 3 months prior to signature of informed consent and suitable for assisted reproductive technology\n* Participants have a normal cervical ThinPrep® cytologic test, (TCT) or Pap smear within 12 months of Screening. If not available, a cervical smear will be performed as part of screening\n* Other protocol defined criteria may apply\n\nExclusion Criteria:\n\n* Participants with history of severe OHSS in any previous ovarian stimulation cycle\n* Participants with Polycystic ovarian syndrome (PCOS) according to Rotterdam modified definition\n* Participants with contraindication to treatment with gonadotropins, hypersensitivity to gonadotropins or to any of the excipients\n* Participants with presence of known or suspected gonadotropin- or estrogen dependent malignancy (example. ovarian-, uterine-, or mammary carcinoma)\n* Participants with ovarian enlargement or cyst of unknown etiology, or presence of an ovarian cyst greater than 25 millimeters before Day 1\n* other protocol defined exclusion criteria may apply",{"count":276,"type":23},266,[278],"PHASE3","The purpose of this study is to assess the efficacy and safety of follitropin alfa\u002Flutropin alfa in Japanese participants with Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) deficiency undergoing Assisted reproductive technology (ART).\n\nThe study duration is approximately 5.5 months for nonpregnant participants and 13 months for participants with confirmed pregnancy in Part A.",[27],[282],"Gonadotropins, infertility, prefilled pen","2026-06-09",{"date":285,"type":44},"2026-06-11",{"date":287,"type":44},"2026-02-05",{"date":289,"type":23},"2028-07-05",{"name":291,"class":179},"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",11,{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":12,"sex":84,"minAge":19,"maxAge":299,"enrollmentInfo":300,"targetDuration":4,"studyType":63,"phases":302,"briefSummary":303,"conditions":304,"keywords":307,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":52},"100643177","a-large-scale-prospective-cohort-study-was-conducted-to-explore-the-association-between-environmental-exposure-and-behavioral-factors-and-infertility-the-success-rate-of-assisted-reproductive-technology-100643177","NCT07641387","A Large-scale, Prospective Cohort Study Was Conducted to Explore the Association Between Environmental Exposure and Behavioral Factors and Infertility (the Success Rate of Assisted Reproductive Technology)","Inclusion Criteria:\n\n* 1\\. Women aged 18 to 46 who use their own eggs or men aged 18 to 55 who use their own sperm; 2. Patients who meet the diagnostic criteria for infertility; 3. Clarify the medical history of persistent infertility for a certain period of time; 4. Voluntarily participate in the project and sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Artificial insemination population with any of the following ARTs contraindications: a. Impairment of sperm and egg combination caused by fallopian tube factors on the female side. b. The female side suffers from acute infection of the reproductive and urinary system or sexually transmitted diseases. c. The female side suffers from genetic diseases, serious physical diseases, and mental and psychological disorders. d. There is a history of birth of babies with congenital defects and it is confirmed that it is caused by female factors. e. The female side is exposed to teratogenic radiation, poisons, and drugs and is in the period of action. f. The female side has bad habits such as alcoholism and drug abuse.\n\n  2\\. First-generation test-tube baby and second-generation test-tube baby population with any of the following ARTs contraindications: a. Any party who provides gametes suffers from acute infection of the reproductive and urinary systems and sexually transmitted diseases or has bad habits such as alcoholism and drug abuse. b. Any party who provides gametes is exposed to teratogenic radiation, poisons, and drugs and is in the period of action. c. The couple who received embryo donation\u002Fegg donation suffers from acute infection of reproductive and urinary system and sexually transmitted diseases, or has bad habits such as alcoholism and drug abuse. d. The woman's uterus is not capable of pregnancy or has a serious physical disease that cannot withstand pregnancy.\n\n  3\\. No embryo transfer after egg retrieval; 4. Frozen embryo transfer is received more than 180 days after egg retrieval.","55 Years",{"count":301,"type":23},5000,[65],"The aim is to explore the reasons for the failure of assisted reproductive technology (ART) in infertile patients in Hunan Province and seek ways to improve the success rate of ART. The study will focus on how environmental exposure (such as environmental pollutants related to plastic products) and lifestyle and social factors affect the success rate of ART in infertile patients.\n\nIn order to explore these issues in depth, the study plans to collect 5,000 samples (male: female ratio 1:1), screen the research subjects from infertile patients who visited Xiangya Third Hospital in Changsha, Hunan Province, and establish a large-scale, prospective infertility patient cohort. By collecting multi-faceted information of the research subjects, including sociodemographic characteristics, lifestyle, basic health status, etc., and conducting long-term follow-up observations, the ART live birth situation of infertile patients is analyzed.\n\nIn terms of research methods, a multivariate analysis method will be used to explore the association between various factors and ART success rate, and a risk prediction model will be constructed. In addition, the study also hopes to clarify the specific reasons for the failure of infertile patients to receive ART, provide a scientific basis for clinical decision-making, and provide guidance for the formulation of environmental protection policies and the improvement of public reproductive health literacy.\n\nIn general, this study, through a large-scale, prospective cohort study, deeply explores the various factors that affect the success rate of ART in infertile patients, and strives to build a risk prediction model in order to improve the success rate of ART and bring more hope to infertile families.",[27,305,306],"Infertility Assisted Reproductive Technology","Infertility (IVF Patients)",[308,309,310,311,312,313],"environmental pollutants","Assisted Reproductive Technology","prospective cohort","life-style","risk factor","social factor","2026-06-08",{"date":285,"type":44},{"date":317,"type":44},"2025-04-01",{"date":319,"type":23},"2035-04-01",{"name":321,"class":51},"The Third Xiangya Hospital of Central South University",{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":86,"enrollmentInfo":329,"targetDuration":4,"studyType":63,"phases":331,"briefSummary":332,"conditions":333,"keywords":336,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":352,"leadSponsor":354,"locationsCount":52},"100638756","theta-healing-based-intervention-in-women-with-polycystic-ovary-syndrome-100638756","NCT07630441","Theta Healing-Based Intervention in Women With Polycystic Ovary Syndrome","The Effect of a Theta Healing-Based Intervention on Fertility Anxiety, Body Self-Compassion, and Body Image in Women Diagnosed With Polycystic Ovary Syndrome: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Women aged 18-45 years\n* Diagnosed with Polycystic Ovary Syndrome (PCOS)\n* Able to read and understand Turkish\n* Voluntary participation in the study\n* Access to a smartphone and internet connection\n\nExclusion Criteria:\n\n* Diagnosed psychiatric disorder\n* Participation in another psychological intervention program\n* Any health condition preventing participation in the intervention sessions\n* Incomplete questionnaire responses",{"count":330,"type":23},142,[65],"This randomized controlled study aims to evaluate the effect of a Theta Healing-based intervention on fertility concerns, self-compassion, and body image in women diagnosed with Polycystic Ovary Syndrome (PCOS). Participants will be randomly assigned to intervention and control groups. The intervention group will receive a structured 5-day Theta Healing-based online intervention program, while the control group will continue routine care. Outcome measures will be assessed at baseline and 6 weeks after the intervention.",[334,27,335],"Polycystic Ovarian Syndrome (PCOS)","Psychological Stress",[337,338,339,340,341,342,343,344,345,346,347],"PCOS","POLYCYSTIC OVARY SYNDROME","THETA HEALING","SELF-COMPASSION","BODY IMAGE","COMPLEMENTARY THERAPY","MEDITATION","REPRODUCTIVE HEALTH","Women's Health","Mind-Body Intervention","fertility anxiety","2026-06-03",{"date":350,"type":44},"2026-06-05",{"date":314,"type":23},{"date":353,"type":23},"2026-09-15",{"name":355,"class":51},"Ankara Medipol University",{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":60,"enrollmentInfo":363,"targetDuration":4,"studyType":63,"phases":365,"briefSummary":366,"conditions":367,"keywords":368,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":52},"100286671","phase-3-fertility-preservation-using-tamoxifen-and-letrozole-in-estrogen-sensitive-tumors-trial-100286671","NCT03011684","Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial","TALES","Inclusion Criteria:\n\n* New breast cancer diagnosis\n* Has not yet begun chemotherapy\n* Desires to undergo ovarian stimulation and oocyte retrieval prior to cancer treatment\n* Age 18 years old or greater\n\nExclusion Criteria:\n\n* Chemotherapy has already commenced or been completed\n* History of recurrent breast cancer (with a prior history of chemotherapy)\n* Stage IV breast cancer diagnosis (metastases remote from the breast)\n* Patient's oncologist advises against the trial - in which case they can choose to receive stimulation with letrozole+gonadotropin\n* Does not plan to undergo ovarian stimulation and oocyte retrieval prior to diagnosis\n* Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow-up, or interpretation of study results\n* Age less than 18 years old",{"count":364,"type":23},309,[278],"Latrogenic infertility as a result of cancer treatment has a profound effect on long-term quality of life in survivors of reproductive-age cancers. Oocyte cryopreservation prior to cancer treatment has been associated with improved quality of life, with a potential ability to reduce long-term decision-related regret in cancer survivors. Though letrozole plus gonadotropin and and tamoxifen plus gonadotropin are currently routinely used worldwide in ovarian stimulation cycles for fertility preservation in patients with estrogen-receptor-positive breast cancer, it is not clear which of the two might lead to improved oocyte yield. Improved knowledge about the efficacy of these medications, with regard to oocyte yield, has the potential to significantly improve quality of life in reproductive-age breast cancer survivors.",[27],[369,370],"Fertility Preservation","Breast Cancer","2026-06-02",{"date":373,"type":44},"2026-06-04",{"date":375,"type":44},"2016-07-21",{"date":377,"type":23},"2028-03-31",{"name":379,"class":51},"University of California, San Francisco",{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":386,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":388,"targetDuration":4,"studyType":63,"phases":390,"briefSummary":391,"conditions":392,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":393,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":52},"100545132","investigating-micro-manipulation-procedures-for-assisted-hatching-timing-100545132","NCT06377917","Investigating Micro-Manipulation Procedures for Assisted Hatching Timing","The IMPACT Trial: Investigating Micro-Manipulation Procedures for Assisted Hatching Timing","IMPACT","Inclusion Criteria for participants:\n\n1. Patients undergoing an IVF cycle with plan for subsequent FET of a single euploid embryo\n2. \\\u003C4 2PNs prior to randomization\n3. Female partners age \\\u003C42 years old at start of VOR cycle\n4. Normal ovarian reserve:\n\n   1. AMH ≥ 1.2 ng\u002FmL\n   2. AFC ≥ 8\n   3. FSH ≤ 12IU\u002FL\n5. BMI \\\u003C38\n6. Patients who desire to transfer the best quality embryo for their embryo transfer.\n\nExclusion Criteria for participants:\n\n1. All patients who do not voluntarily give their written consent for participation\n2. Patients with a prior failed IVF cycle - defined as no blastocysts\n3. Patients with a history of more than one failed euploid embryo transfer\n4. Donor oocyte cycles\n5. Gestational Carriers\n6. Male partner with \\\u003C100,000 total motile spermatozoa per ejaculate (donor sperm is acceptable)\n7. Use of surgical procedures to obtain sperm\n8. Communicating hydrosalpinges without a plan for surgical correct prior to frozen embryo transfer\n9. Endometrial Insufficiency, as defined by a prior cycle with maximal endometrial thickness \\\u003C6mm,), or persistent endometrial fluid\n10. Single gene disorders, chromosomal translocations, or any other disorders requiring a more detailed embryo genetic analysis than standard PGT-A",{"count":389,"type":23},75,[65],"This study aims to assess the clinical significance of cleavage stage (Day 3) assisted hatching compared to assisted hatching at the blastocyst stage (Day 5,6,7) of embryo development at the time of trophectoderm (TE) biopsy for patients undergoing in vitro fertilization (IVF) and preimplantation genetic testing for aneuploidy (PGT-A) for treatment of their infertility.",[27],{"date":348,"type":44},{"date":395,"type":44},"2026-05-31",{"date":397,"type":23},"2028-05-31",{"name":399,"class":51},"Reproductive Medicine Associates of New Jersey",{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":188,"sex":84,"minAge":19,"maxAge":407,"enrollmentInfo":408,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":410,"conditions":411,"keywords":412,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":414,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":52},"100149633","discarded-materials-study-100149633","NCT01219335","Discarded Materials Study","Laboratory Evaluation of De-identified, Developmentally Arrested Embryos of Embryos Diagnosed as Having an Abnormal Number of Chromosomes for Optimization of Techniques for Assisted Reproduction","Inclusion Criteria:\n\nnone\n\nExclusion Criteria:\n\nnone","65 Years",{"count":409,"type":23},10000,"Use of discarded embryos to advance laboratory expertise and technology in the area of human embryo development and assisted reproductive technologies",[27],[413],"IVF",{"date":348,"type":44},{"date":416,"type":4},"2003-04",{"date":418,"type":23},"2029-12",{"name":399,"class":51},{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":426,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":226,"minAge":428,"maxAge":429,"enrollmentInfo":430,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":432,"conditions":433,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":441,"leadSponsor":443,"locationsCount":4},"100638814","prospectivemaleaya---frequency-and-prediction-of-therapy-induced-testicular-dysfunction-in-aya-cancer-survivors-100638814","NCT07612943","ProspectiveMaleAYA - Frequency and Prediction of Therapy-induced Testicular Dysfunction in AYA Cancer Survivors","Frequency and Prediction of Therapy-induced Testicular Dysfunction in AYA Cancer Survivors (ProspectiveMaleAYA)","FertiTestAYA","Inclusion Criteria:\n\n* Subjects with male internal and external genitalia\n* Age at cancer diagnosis 15-39 years old\n* Subjects planned to or having received oncologic treatment\n* Subjects able to provide semen sample\n* Information available on cancer treatment and medical history\n* Patients (or parents in case of minors) who signed informed consent\n\nExclusion Criteria:\n\n* individuals presenting with relapse or secondary cancers at time of inclusion\n* subjects who were not treated with oncological treatment\n* subjects who underwent bilateral orchiectomy\n* patients with a diagnosis of azoospermia or testicular failure previously to cancer diagnosis","15 Years","39 Years",{"count":431,"type":23},1000,"This study describes the ProspectiveMaleAYA cohort, a multicentre, prospective, longitudinal European study designed to investigate the long-term impact of cancer and cancer treatments on reproductive and endocrine health in adolescent and young adult (AYA) male cancer patients. Addressing major gaps in standardized prospective data, particularly for long-term fertility, hypogonadism, and the effects of newer systemic therapies, the study will harmonize data collection across centres and follow patients from diagnosis through post-treatment survivorship.\n\nComprehensive clinical, oncologic, reproductive, hormonal, biological, and patient-reported outcomes will be collected at predefined intervals to evaluate testicular dysfunction, fertility impairment, oligo\u002Fazoospermia, sexual health, and quality of life. Sub-cohorts will enable focused analyses of genetic and epigenetic sperm changes, whole-genome sequencing to identify susceptibility to reproductive and organ toxicity, accelerated aging markers following specific treatments, access to and satisfaction with fertility counselling, and sexual health dysfunctions. The overarching aim is to identify risk factors and predictive markers, develop individualized risk stratification and prediction models, and support precision, patient-centred survivorship care for male AYA cancer survivors.",[434,435,27,436],"Cancer","Reproduction","Late Effects","2026-05-28",{"date":439,"type":44},"2026-05-29",{"date":71,"type":23},{"date":442,"type":23},"2031-05-31",{"name":444,"class":51},"Karolinska Institutet",{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":84,"minAge":428,"maxAge":429,"enrollmentInfo":452,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":454,"conditions":455,"keywords":459,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":465,"completionDateStruct":466,"leadSponsor":468,"locationsCount":4},"100638517","late-effects-of-cancer-therapies-on-gonadal-function-fertility-efficiency-of-fertility-preservation-procedures-and-pregnancy-outcomes-100638517","NCT07622537","Late Effects of Cancer Therapies on Gonadal Function, Fertility, Efficiency of Fertility Preservation Procedures and Pregnancy Outcomes","Follow-AYA","Inclusion Criteria:\n\n* Female and male cancer patients aged between 15 and 39 years at diagnosis.\n* First diagnosed with any cancer disease between 01\u002F01\u002F2000 and 31\u002F12\u002F2025\n* Treated with chemotherapy and\u002For targeted therapy\u002Fimmunotherapy and\u002For radiotherapy\u002F radioactive iodine therapy and\u002For testis\u002Fscrotal or gynaecological surgery.\n* Information on treatment received available.\n\nExclusion Criteria:\n\n* Pre-existing known POI at cancer diagnosis\n* Cancer treated by surgery alone (except gynaecological\u002Ftesticular surgery)\n* Data from second malignant neoplasm diagnose and treatment\n* Adult subject of a measure of legal protection and\u002For patients with serious mental disorders",{"count":453,"type":23},4000,"In the past two decades, evidence-based knowledge on the prevalence and risk factors for fertility impairment, including infertility, following cancer and numerous cancer treatment regimens has significantly increased. However, data remains mostly insufficient for individualized prediction of (future) fertility potential, including success of artificial reproductive technologies (ART). Furthermore, therapies have become increasingly complex. Recent treatment regimens have continuously implemented novel treatment approaches (e.g. immune therapies such as checkpoint inhibitors) for which no comprehensive data regarding its impact on fertility and pregnancy outcomes is available, yet.\n\nIt is crucial to carefully balance risk-benefit between fertility preservation (FP) procedures and potential of gonadal function\u002Ffertility impairment, to examine the efficiency and safety, as well as to assess patients' satisfaction regarding the FP procedures. Answering these questions is highly relevant as it has been shown that fertility capacity and post-treatment gonadal function may represent a significant part of the quality of life in young cancer survivors.\n\nThe study therefore aim to set up a large-scale network structure of emerging data collection programmes to evaluate the gonadotoxic risks, including the prevalence and course of ovarian\u002Ftesticular dysfunction and\u002For fertility impairment and premature ovarian insufficiency\u002Foligo\u002Fazoospermia following specific treatments, identification of further risk factors and predictive markers to enhance precision survivorship research in this field. Additionally, data on the use of fertility preservation\u002Ffertility treatment and patients' satisfaction related to these procedures in Europe shall be analysed to support patient-centric care.\n\nReproductive health counselling should not be restricted to evaluating the individual risk of gonadotoxicty and offering fertility preservation to those at risk. It also includes the sexual health, the use of post-cancer treatment contraception for those recommended to delay attempting pregnancy after a cancer diagnosis and the identification of potential obstetrical and neonatal risks to provide individualized, risk-adapted follow-up during pregnancy. An increased risk of obstetrical and neonatal complications has been reported for several conditions, including preterm delivery, pre-eclampsia, cardiac dysfunction, and gestational diabetes. Most available studies are based on population registry and lack of detailed information on critical factors such as the impact of the timing of pregnancy, method of conception or the type of cancer treatment received (e.g pelvic irradiation, anthracycline, targeted therapy, immunotherapy…), all of which may influence the outcomes.\n\nThe main objectives of this retrospective analysis of European ongoing adolescent and young adult (AYA) cancer patient cohorts are:\n\n• To establish harmonized databases with clinical data on pre- and post-cancer therapy and reproductive outcomes in AYA patients followed longitudinally.\n\n• To evaluate the impact of cancer treatment on long-term fertility according to cancer type and individual patients' characteristics (pre- and post-treatment) in male and female AYA populations.\n\n• To evaluate effect of cancer therapies on ovarian function in female AYA patients\n\n• To evaluate long-term effect on the endocrine function of the testis in male AYA patients i.e., the frequency of hypogonadism.\n\n• To evaluate the obstetrical and neonatal outcomes according to the disease and treatment.",[434,27,436,456,457,458],"Female Fertility","Male Fertility","AYA Cancer Survivors",[460,461,462],"cancer treatment induced late effects","infertility after cancer","AYA cancer survivours","2026-05-27",{"date":348,"type":44},{"date":71,"type":23},{"date":467,"type":23},"2035-07-31",{"name":444,"class":51},{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":475,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":18,"minAge":428,"maxAge":429,"enrollmentInfo":477,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":479,"conditions":480,"keywords":487,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":492,"startDateStruct":493,"completionDateStruct":494,"leadSponsor":496,"locationsCount":4},"100637786","prospectivefemaleaya---late-effects-of-cancer-therapies-on-gonadal-function-fertility-efficiency-of-fertility-preservation-procedures-and-pregnancy-outcomes-100637786","NCT07622420","ProspectiveFemaleAYA - Late Effects of Cancer Therapies on Gonadal Function, Fertility, Efficiency of Fertility Preservation Procedures and Pregnancy Outcomes","Late Effects of Cancer Therapies on Gonadal Function, Fertility, Efficiency of Fertility Preservation Procedures and Pregnancy Outcomes (ProspectiveFemaleAYA)","FemFertilAYA","Inclusion Criteria:\n\n* Female cancer patients aged between 15 and 39 years at diagnosis.\n* Receiving a diagnosis of primary cancer 01\u002F01\u002F2025 or later\n* Treated with chemotherapy and\u002For targeted therapy\u002Fimmunotherapy and\u002For radiotherapy\u002F radioactive iodine therapy and\u002For gynaecological surgery.\n* Detailed information on treatment received available.\n\nExclusion Criteria:\n\n* Pre-existing known POI at cancer diagnosis.\n* Treated by surgery alone (except gynaecological surgery).\n* Patients with relapse or secondary malignant neoplasms at time of inclusion or having received already treatments for cancer\n* Adult individuals subject of a measure of legal protection and\u002For patients with severe mental disorders.",{"count":478,"type":23},3000,"In the past two decades, the evidence-based knowledge on the prevalence and risk factors for gonads impairment, including infertility, following cancer and numerous cancer treatment regimen has significantly increased. However, data remains mostly insufficient for individualized prediction of (future) fertility and pregnancy potential, including the use and success of artificial reproductive technologies (ART). Furthermore, therapies have become increasingly complex as more recent treatment regimen have continuously also implemented novel treatment approaches (e.g. immune therapies such as checkpoint inhibitors) for which no comprehensive data regarding its impact on fertility and pregnancy outcomes is available, yet.\n\nIt is crucial to carefully balance risk-benefit between fertility preservation (FP) procedures and potential of gonadal function\u002Ffertility impairment, to examine the efficiency and safety, as well as to assess patients' satisfaction regarding the FP procedures. Answering these questionsis highly relevant as it has been shown that fertility capacity and post-treatment gonadal function may represent a significant part of quality of life in young cancer survivors.\n\nThe study therefore aim to set up a large-scale registry of emerging data collection programmes to evaluate the gonadotoxic risks, including the prevalence and course of ovarian dysfunction and\u002For fertility impairment and premature ovarian insufficiency following specific treatments, identification of further risk factors and predictive markers to enhance precision survivorship research in this field. Additionally, data on the use of fertility preservation\u002Fhormonal treatment and patients' satisfaction related to these procedures in Europe will be analysed to support patient-centric care.\n\nReproductive health counselling should not be limited to evaluating the risk of gonadotoxicity and offering fertility preservation to those at risk. It should also include evaluating the impact on post-treatment sexuality, menopausal symptoms management, and the counselling on contraception.\n\nIn addition to clinical information, whole genome sequence data will be generated for selected study participants with evidence of varying impact of gonadotoxic therapies on reproductive function to find genetic variants associated with risk of reproductive and organ toxicity.\n\nThe data collection will focus on all different cancer diseases, including diseases which are less common such as different types of sarcomas. This will be a significant development to the current state of information in existing registries.\n\nThe primary objectives of this prospective analysis of European ongoing adolescent and young adult (AYA) cancer patient cohorts are:\n\n1. To establish a database with relevant clinical characteristics at time of diagnosis, cancer therapy received and post-cancer clinical and reproductive outcomes by following AYA cancer patients longitudinally.\n2. To evaluate the effect of cancer therapies on ovarian function and reproductive potential.\n3. To evaluate fertility preservation measures performed, their risks and efficacy.\n4. To evaluate the impact of fertility preservation measures on the risk of cancer relapse.\n5. To evaluate occurrence of pregnancies\u002Flive births naturally conceived (including unplanned) or through medical assistance post-cancer and the obstetrical complications and neonatal health following the use of cryopreserved oocytes or gonadal tissue.\n6. To set up a genetic database based on whole genome sequencing of AYAs of the cohort. For this objective a Substudy 1 : \" Development of risk prediction models based on clinical and genetic data \" will be conducted.\n7. To develop prediction models for organ toxicities in cancer patients (objective included in Substudy 1).\n8. To evaluate the effect of cancer therapies on sexuality and quality of life. For this objective a Substudy 2 : \"Sexual Health\" will be conducted.\n9. To evaluate the use and counselling on contraception. For this objective, a Substudy 3 : \"Contraception\" will be conducted.\n10. To describe management of treatment-induced premature ovarian insufficiency (POI) and menopausal symptoms. For this objective a Substudy 4 \"Management of POI and Menopause Symptoms\" will be conducted.\n11. To explore patient's satisfaction receiving counseling and\u002For undergoing fertility preservation. For this objective a Substudy 5 on \"Satisfaction with Fertility Preservation\" will be conducted.",[434,481,27,482,436,483,484,485,486],"Cancer in Pregnancy","In Vitro Fertilisation (IVF) Treatment","Quality of Life","Sexual Health Quality of Life","POI","Contraception Use",[488,489,490,491],"cancer therapy induced late effects","AYA cancer survivors","infertility as a late effect of cancer","late effects prediction",{"date":348,"type":44},{"date":71,"type":23},{"date":495,"type":23},"2035-05-31",{"name":444,"class":51},{"id":498,"slug":499,"hasResults":12,"nctId":500,"briefTitle":501,"officialTitle":502,"acronym":4,"eligibilityCriteria":503,"healthyVolunteers":188,"sex":18,"minAge":85,"maxAge":60,"enrollmentInfo":504,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":506,"conditions":507,"keywords":508,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":52},"100639747","clinical-value-of-saline-infusion-sonohysterography-in-the-assessment-of-cesarean-scar-defects-100639747","NCT07610668","Clinical Value of Saline Infusion Sonohysterography in the Assessment of Cesarean Scar Defects","Preliminary Clinical Application Study of Saline Infusion Onohysterography in Structure of Cesarean Scar Surgery","Inclusion Criteria:\n\n* More than 6 months after cesarean delivery;\n* Presenting with clinical symptoms-including abnormal uterine bleeding, dysmenorrhea, prolonged menstrual spotting, or secondary infertility;\n* Requiring saline infusion sonohysterography (SIS) to evaluate the cesarean scar.\n\nExclusion Criteria:\n\n* Multiple cesarean deliveries;\n* Patients contraindicated for saline infusion sonohysterography (SIS), including pregnancy or suspected pregnancy, failure to meet vaginal hygiene criteria, inability to cooperate during the procedure, or suboptimal image quality;\n* Cases with incomplete clinical data or lost to follow-up.",{"count":505,"type":23},300,"This study selected patients who underwent cesarean section and were scheduled to undergo Saline Infusion Sonohysterography (SIS) for evaluating the structure of the incision. Clinical characteristics and clinical symptoms were collected. Combined with hysteroscopy, MRI, conventional ultrasound and SIS examination results, the study analyzed the detection rate of cesarean section diverticula by SIS, the changes in diverticulum size and the diagnostic efficacy of residual muscle layer thickness at the incision site. The surgical methods and clinical symptom improvement of patients with CSD after surgery were followed up for half a year to one year. The study aimed to clarify the guiding value of SIS in clinical decision-making and patient prognosis for patients, and to analyze the etiological relationship between the true incidence of CSD and clinical complications. Thus, it provided evidence-based basis for clinical events of cesarean section surgery → CSD → CSD complications → surgical treatment of CSD → patient prognosis, promoting the progress of precise diagnosis and treatment of female reproductive health.",[27],[509,510,511,512],"Saline Infusion Sonohysterography","Transvaginal ultrasonography","Cesarean scar diverticulum","Residual myometrial thickness","2026-05-26",{"date":437,"type":44},{"date":516,"type":44},"2023-01-01",{"date":518,"type":23},"2026-07-31",{"name":520,"class":51},"Tang-Du Hospital",{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":525,"acronym":4,"eligibilityCriteria":526,"healthyVolunteers":188,"sex":84,"minAge":19,"maxAge":527,"enrollmentInfo":528,"targetDuration":4,"studyType":63,"phases":530,"briefSummary":531,"conditions":532,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":533,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":52},"100477715","sex-selection-of-human-spermatozoa-100477715","NCT05500573","Sex Selection of Human Spermatozoa","Inclusion Criteria:\n\n* Couples undergoing infertility treatment with IVF or insemination seeking gender specific offspring for medical and non medical reasons\n\nExclusion Criteria:\n\n* Severe male factor","89 Years",{"count":529,"type":23},2000,[65],"This study aims to demonstrate a reliable method of selecting gender specific sperm. X-bearing spermatozoa and Y-bearing spermatozoa will be identified from the density gradient layers. The selected gender specimen will then be utilized for assisted reproductive fertilization- in vitro fertilization or intrauterine insemination which are routine standard of care procedures.",[27,413],{"date":439,"type":44},{"date":535,"type":44},"2013-11-06",{"date":537,"type":23},"2029-12-31",{"name":539,"class":51},"Weill Medical College of Cornell University",{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":546,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":548,"enrollmentInfo":549,"targetDuration":550,"studyType":24,"phases":4,"briefSummary":551,"conditions":552,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":76},"100640629","fertility-outcomes-after-antibiotic-treatment-in-women-with-chronic-endometritis-100640629","NCT07603492","Fertility Outcomes After Antibiotic Treatment In Women With Chronic Endometritis","Monitoring of Reproductive Outcomes in Women With Chronic Endometritis: A Prospective Cohort Study on the Impact of Antibiotic Treatment on Fertility and Obstetric Outcomes","MORE","Inclusion Criteria\n\n* Female participants aged 18-40 years.\n* Diagnosis of infertility (primary or secondary infertility).\n* Indication for diagnostic hysteroscopy with endometrial biopsy as part of infertility evaluation.\n* Suspected or confirmed chronic endometritis.\n* Ability and willingness to provide written informed consent prior to any study-related procedures.\n* Willingness to undergo protocol-defined antibiotic treatment.\n* Willingness to comply with study procedures and follow-up assessments.\n* Agreement to reproductive outcome monitoring following treatment, including spontaneous conception and pregnancies achieved through assisted reproductive technologies (ART).\n\nExclusion Criteria\n\n* Age \\>40 years.\n* Current pregnancy.\n* Known hypersensitivity or contraindication to tetracycline antibiotics or other study-related antibiotic therapy without a suitable alternative treatment option.\n* Severe systemic disease or medical condition that, in the opinion of the investigator, could interfere with study participation, safety, or interpretation of study results.\n* Active malignant disease requiring systemic treatment.\n* HIV infection or other severe immunodeficiency disorder.\n* Acute pelvic inflammatory disease or clinically significant active genital tract infection requiring immediate treatment.\n* Previous participation in this study.\n* Inability to undergo planned hysteroscopy or endometrial biopsy.\n* Inability or unwillingness to comply with study procedures or follow-up requirements.\n* Failure or refusal to provide written informed consent.","40 Years",{"count":110,"type":23},"2 Years","Chronic endometritis (CE) is a long-lasting inflammation of the lining of the uterus. Many women with CE do not have symptoms, but the condition may affect fertility, embryo implantation, and pregnancy outcomes. CE is usually diagnosed during hysteroscopy, a procedure that allows doctors to look inside the uterus and collect a small tissue sample for laboratory testing.\n\nThe goal of this prospective cohort study is to learn how common CE is in women with infertility and to determine whether antibiotic treatment improves reproductive outcomes. The study will also examine whether hysteroscopic findings match laboratory-confirmed CE and whether certain findings can help doctors diagnose CE more accurately. In addition, researchers will study the types of bacteria found in the uterine lining and their possible relationship to fertility and pregnancy outcomes.\n\nThe main questions the study aims to answer are:\n\n* How common is chronic endometritis in women undergoing infertility evaluation?\n* Does antibiotic treatment improve fertility and pregnancy outcomes in women with CE?\n* Can hysteroscopic findings reliably predict CE confirmed by laboratory testing?\n* Are specific bacteria associated with poorer reproductive outcomes? Researchers will enroll approximately 100 women aged 18 to 40 years with diagnosed infertility who are scheduled for hysteroscopy and endometrial biopsy as part of infertility evaluation. Participants with severe systemic disease, pregnancy, inability to undergo hysteroscopy or antibiotic treatment, or allergy to study antibiotics without a suitable alternative will not be included.\n\nParticipants will:\n\n* Undergo diagnostic hysteroscopy and endometrial biopsy\n* Have tissue samples examined using histopathology and immunohistochemistry to identify CE\n* Receive standardized antibiotic treatment if CE is confirmed\n* Be followed for up to 12 months after treatment to monitor fertility outcomes\n* Continue follow-up during pregnancy, if pregnancy occurs, to assess pregnancy and delivery outcomes Researchers will evaluate spontaneous pregnancies, embryo transfer success, implantation rates, miscarriage rates, time to pregnancy, and live birth outcomes. Pregnancy complications such as preeclampsia, placental disorders, premature rupture of membranes, and preterm birth will also be recorded.\n\nThe study is expected to run from January 2026 through December 2029. Data collected during the study may help improve the diagnosis and treatment of chronic endometritis in women with infertility and may support better reproductive outcomes in clinical practice.",[553,27,554,555],"Endometritis","Hysteroscopy","Pregnancy Disease","2026-05-22",{"date":463,"type":44},{"date":559,"type":44},"2026-01-01",{"date":561,"type":23},"2030-01-01",{"name":563,"class":564},"Faculty Hospital Kralovske Vinohrady","OTHER_GOV",{"id":566,"slug":567,"hasResults":12,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":571,"eligibilityCriteria":572,"healthyVolunteers":188,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":573,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":575,"conditions":576,"keywords":581,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":589,"completionDateStruct":590,"leadSponsor":592,"locationsCount":52},"100633290","female-reproductive-health-in-canadian-armed-forces-100633290","NCT07524764","Female Reproductive Health in Canadian Armed Forces","Female Reproductive Health in Canadian Armed Forces: Experience, Access to Care, and Support","BEARH2025","Inclusion Criteria (part 1):\n\n* Female (biological sex)\n* Aged at least 18 years old\n* Completed Basic Military Qualification (including Regular Forces, Reserve Forces (Class A, B, or C), Canadian Rangers, COATS instructors, and survivors of the LGBT Purge whose official records of service have been changed to reflect the nature of their discharge)\n\nInclusion Criteria (part 2):\n\n* Female (biological sex)\n* Aged at least 18 years old\n* Completed Basic Military Qualification (including Regular Forces, Reserve Forces (Class A, B, or C), Canadian Rangers, COATS instructors, and survivors of the LGBT Purge whose official records of service have been changed to reflect the nature of their discharge)\n* Have experienced a reproductive health issue while serving in the CAF\n\nInclusion Criteria (part 3):\n\n* Healthcare providers (CAF Health Services, public servant, civilian) who has treated female patients who are actively serving and\u002For Veterans of the CAF in the past 5 years.\n* Stakeholders who are involved in supporting reproductive health of female members of the CAF and\u002For Veterans.\n* Policymakers who are involved in supporting reproductive health of female members of the CAF and\u002For Veterans.",{"count":574,"type":23},1121,"This is a mixed-method study aimed at gathering new evidence on reproductive health among female service members in the Canadian Armed Forces (CAF). Reproductive health includes four primary domains: contraception; undesired reproductive outcomes (including unintended pregnancy, adverse pregnancy outcomes, and infertility); assisted reproductive care; and pelvic floor dysfunctions. Additional factors that may influence reproductive outcomes will also be explored, including gynecological health (including but not limited to menstrual health, menopause, breast injury, sexually transmitted and blood-borne infections) as well as physical and psychological health (including but not limited to repetitive strain injuries, depression, and post-traumatic stress disorder). Evidence gathered on reproductive health issues will include, but not limited to, the lived experiences (occurrence), associated risk factors, access to care, including barriers and facilitators, service utilization, and career-related impacts among actively serving members and Veterans of the CAF. These will inform the development of recommendations and support services aimed at improving reproductive health care within the CAF. This project is divided into 3 convergent parts:\n\nPart 1: An online pan-Canadian survey that will achieve a minimum total sample of 1067 participants.\n\nPart 2: Semi-structured individual interviews (open-ended questions) will be conducted with female CAF members and Veterans who have experienced at least one reproductive health issues. A total of 30 participants are estimated to be required to achieve data saturation across the four primary domains.\n\nPart 3: Semi-structured group discussion (open-ended questions) will be conducted with healthcare providers, who have experience with treating female reproductive health issues in CAF members, as well as stakeholders and policymakers involved in supporting female members of the CAF\u002FVeterans. A total of 24 healthcare providers\u002Fstakeholders\u002Fpolicymakers will form 3 group discussion (8 participants\u002Fgroup).\n\nFor all 3 parts, efforts in recruitment will be made to ensure representation across CAF elements, minority groups, and native language (French and English).",[577,578,579,580,27,345],"Pregnancy","Pelvic Floor Dysfunction","Military Personnel","Contraception",[582,583,577,27,584,580,585,586],"Reproductive health issue","Women's health","Pelvic floor dysfunction","Canadian Armed Forces","Military personnel","2026-05-19",{"date":556,"type":44},{"date":587,"type":44},{"date":591,"type":23},"2026-12-15",{"name":593,"class":51},"Université de Sherbrooke",{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":188,"sex":18,"minAge":19,"maxAge":601,"enrollmentInfo":602,"targetDuration":4,"studyType":63,"phases":604,"briefSummary":605,"conditions":606,"keywords":615,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":630,"locationsCount":52},"100629184","pesticides-and-infertility-oxidative-stress-via-circulating-cell-free-dna-and-gutgenital-microbiome-signatures-in-women-with-endometriosis-100629184","NCT07471373","Pesticides and Infertility: Oxidative Stress Via Circulating Cell-free DNA and Gut\u002FGenital Microbiome Signatures in Women With Endometriosis","PestiEndoMicro","Inclusion Criteria:\n\n* The \"case\" group will include:\n* All women aged 18 to 43, with confirmed endometriosis and endometriosis grade 3 or 4 as defined by the 1985 revised version of the American Society of Reproductive Medicine.\n* The \"control\" group will include:\n* All women aged between 18 and 43, whose infertility problem is proven male infertility and who do not have endometriosis identified by biological, genetic and clinical tests.\n* The following criteria will apply to both groups:\n* All women who have not received antibiotic treatment in the three months preceding inclusion and who are not participating in any pharmacological study.\n* All women who are covered under the national social security health insurance scheme.\n* All women who have signed a written informed consent form, thereby confirming their participation in the study after a period of free and informed reflection.\n\nExclusion Criteria:\n\n* All women aged 44 and over.\n* Women who are overweight, obese or anorexic.\n* Women taking antibiotics 3 months prior to inclusion, or participating in a drug study.\n* All women under anti-GnRH treatment, pregnant or suffering from a chronic inflammatory disease such as Crohn's disease, polycystic ovary syndrome, etc.\n* All women whose endometriosis has not been formally confirmed by the tests offered by the Reproductive Medicine and Biology Department, CECOS de Picardie, CHU Amiens-Picardie.\n* All patients under guardianship, curators or safeguard of justice.\n* All patients who have not signed the written consent confirming their participation in the study, after a period of free and informed reflection.\n* Any patient who withdraws her consent for participation in the study.","43 Years",{"count":603,"type":23},160,[65],"This project PestiEndoMicro aims to provide an innovative approach, studying endometriosis under the genital and gut microbiota scope. To realize this project, the investigators are planning to dose cfDNA to assess the oxidative stress caused by endometriosis and study its epigenetics. At the same time, the investigators will take a pragmatic approach by assessing pesticide exposure in these patients and estimate the correlation between gut or genital dysbiosis and chemical agent exposure. Also, the investigators will take the initiative to use classic culture, qPCR techniques, and NGS to establish signatures in vaginal, endometrial and gut microbiota in patients with endometriosis. With these approaches, the goal is to gain more knowledge about endometriosis and optimize early diagnosis by establishing a signature in the genital and gut microbiota, but also by dosing the cfDNA. By doing so the investigators could open new opportunities to develop new therapeutic strategies for endometriosis.",[607,27,456,608,609,610,611,612,613,614],"Endometriosis","Cell Free DNA","Genital Microbiota","Vaginal Microbiota","Endometrial Microbiota","Pesticides","Gut Microbiota","Epigenetics",[607,27,616,617,618,619,620,621,622,623],"Female fertility","cell free DNA","genital microbiota","vaginal microbiota","endometrial microbiota","pesticides","gut microbiota","epigenetics","2026-05-12",{"date":626,"type":44},"2026-05-15",{"date":628,"type":44},"2026-02-27",{"date":98,"type":23},{"name":631,"class":51},"Centre Hospitalier Universitaire, Amiens",{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":638,"eligibilityCriteria":639,"healthyVolunteers":12,"sex":226,"minAge":19,"maxAge":299,"enrollmentInfo":640,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":641,"conditions":642,"keywords":644,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":660,"completionDateStruct":662,"leadSponsor":664,"locationsCount":52},"100478765","measuring-free-radicals-in-human-sperm-cells-related-to-microbiota-and-lifestyle-factors-100478765","NCT05514223","Measuring Free Radicals in Human Sperm Cells Related to Microbiota and Lifestyle Factors","MeaSuring Free radIcals With Diamond magnetometrRy In hUman Single Sperm Cells Related to Microbiota and Lifestyle Factors","SIRIUS","Inclusion Criteria:\n\n* Males of couples visiting the CRM at the UMCG between 18-55 years old.\n* Planned semen-analysis as standard care.\n\nExclusion Criteria:\n\n* Males who receive(d) chemo- and\u002For radiotherapy, use(d) testosterone suppletion and\u002For anabolic steroids\n* Males who are azoospermic\n* Males who have an abnormal SA due to genetic causes.\n* Semen analysis with round cells \\>2x106 \u002Fml (as marker for infection)\n* Males who currently use antibiotics",{"count":62,"type":23},"The cause of infertility can be due to a female factor or a male factor. In case of a male factor, it is often due to poor semen quality. However, the cause of poor quality is often unknown. In previous research, infertility problems in men were related to chemical processes in metabolism causing the formation of free radicals. Free radicals are physiological by-products of our body mechanisms. Free radicals are very reactive and can therefore react with a lot of molecules of cells within our body and cause damage. A balance between free radicals, which are also needed for physiological processes in the body, and antioxidants, which defuses the reactive free radicals, is most desirable. However, as stated in literature, there are a lot of factors that can influence extra free radical production, which causes overloading of the system, resulting in damage on cellular level. Free radicals in semen plasma and on the sperm cell could play a role in male infertility. Nonetheless, free radicals are not used as diagnostic markers due to the lack of detection systems, as free radicals are very short-lived. This study aims to introduce a new technique, called diamond magnetometry, to measure free radicals directly on the sperm cell and in serum. Diamond magnetometry involves very small diamond particles as magnetic sensors that engage a reaction with the free radicals on the sperm cell, causing signals that can be measured. To compare local free radical production with systemic free radical production, other diagnostic biomarkers are also measured in serum.\n\nIt is hypothesized that the composition of seminal microbiome could influence the free radical concentration. Therefore, this study also aims to explore the microbiota composition and see if this has an influence in semen quality and free radical production. At last, this study also want to correlate standard semen parameters (defined by the World Health Organisation), lifestyle factors and food intake, to detect a role for lifestyle in the production of free radicals.",[643,27],"Infertility, Male",[645,646,647,648,649,169,650,651,652,653,654,655,656],"Free radicals","Reactive oxygen species","Microbiota","Diet","Dietary patterns","Semen analysis","Fertility clinics","Diamond magnetometry","Lifestyle","Semen","Oxidative stress","Food frequency questionnaire","2026-05-07",{"date":659,"type":44},"2026-05-08",{"date":661,"type":44},"2024-06-01",{"date":663,"type":23},"2027-09-30",{"name":665,"class":51},"University Medical Center Groningen",{"id":667,"slug":668,"hasResults":12,"nctId":669,"briefTitle":670,"officialTitle":671,"acronym":4,"eligibilityCriteria":672,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":548,"enrollmentInfo":673,"targetDuration":4,"studyType":63,"phases":675,"briefSummary":677,"conditions":678,"keywords":679,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":683,"lastUpdatePostDateStruct":684,"startDateStruct":686,"completionDateStruct":687,"leadSponsor":689,"locationsCount":52},"100636717","phase-2-successive-doses-of-gnrh-agonist-versus-single-dose-of-gnrh-agonist-to-trigger-ovulation-in-hyper-responders-100636717","NCT07569315","Successive Doses of GnRH Agonist Versus Single Dose of GnRH Agonist to Trigger Ovulation in Hyper-responders","Successive Doses of GnRH Agonist Versus Single Dose of GnRH Agonist to Trigger Ovulation in Hyper-responders Undergoing IVF Cycle : A Randomized Controlled Study.","Inclusion Criteria:\n\n* GnRH antagonist IVF cycle\n* Hyper-responders to induction of ovulation\n\nExclusion Criteria:\n\n* Hypogonadotrophic hypogonadism\n* Endometriosis\n* History of recurrent abortion",{"count":674,"type":23},190,[676],"PHASE2","The aim of this randomized controlled study is to compare the efficacy of three successive doses of a GnRH agonist ( administered 36 , 24 and 12 hours before oocyte retrieval ) with a single dose of a GnRH agonist ( administered 36 hours before oocyte retrieval ) in triggering ovulation in hyper-responders",[27],[27,680,681,682,337],"GnRH agonist trigger","IVF-ET","Hyper-responders","2026-05-06",{"date":685,"type":44},"2026-05-11",{"date":71,"type":23},{"date":688,"type":23},"2028-04-01",{"name":690,"class":51},"Bedaya Hospital"]